Purine Salvage Pathway Mechanism and Clinical Significance

Introduction to the Purine Salvage Pathway

The purine salvage pathway is a cellular mechanism that interconverts and recycles endogenous purines to regenerate nucleotides, providing an energetically favorable alternative to de novo synthesis, as noted by the British Journal of Dermatology 1, 2

Azathioprine metabolism illustrates the purine salvage pathway, where azathioprine is converted to 6-mercaptopurine (6-MP) and then enters the purine salvage pathway, involving enzymes such as hypoxanthine guanine phosphoribosyl transferase (HPRT) 1, 2
6-MP is metabolized through three competing pathways, including conversion to active 6-thioguanine nucleotides via HPRT, oxidation to inactive 6-thiouric acid via xanthine oxidase, and methylation to inactive 6-methyl mercaptopurine via thiopurine methyltransferase (TPMT) 2, 3

Genetic polymorphisms in TPMT affect azathioprine metabolism, with approximately 10% of individuals carrying a low-activity variant allele that increases risk of toxicity, as reported by the British Journal of Dermatology 1, 2
Individuals with undetectable TPMT activity (0.3% of population) are at high risk for severe myelosuppression with conventional azathioprine doses 2, 3
Mycophenolate mofetil (MMF) interferes with T-cell proliferation by blocking the de novo synthesis of guanine nucleotides, affecting both B and T lymphocytes, according to Praxis Medical Insights 4